Mechanisms of ginsenosides exert neuroprotective effects on spinal cord injury: A promising traditional Chinese medicine

Qi, Le; Zhang, Jun; Wang, Jinghong; An, Junyan; Wang, Xue; Liu, Qinyi; Zhang, Yan

doi:10.3389/fnins.2022.969056

Cited by 4 publications

(2 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…205 Traditional Chinese medicines, such as ginsenosides, genistein and tanshinone, also mediate neuroprotection and promote neural function recovery of SCI. [206][207][208][209] Neurotrophic factors. The roles of different neurotrophic factors vary.…”

Section: Intervention and Repair Of Scimentioning

confidence: 99%

Spinal cord injury: molecular mechanisms and therapeutic interventions

Ren

et al. 2023

Sig Transduct Target Ther

View full text Add to dashboard Cite

Spinal cord injury (SCI) remains a severe condition with an extremely high disability rate. The challenges of SCI repair include its complex pathological mechanisms and the difficulties of neural regeneration in the central nervous system. In the past few decades, researchers have attempted to completely elucidate the pathological mechanism of SCI and identify effective strategies to promote axon regeneration and neural circuit remodeling, but the results have not been ideal. Recently, new pathological mechanisms of SCI, especially the interactions between immune and neural cell responses, have been revealed by single-cell sequencing and spatial transcriptome analysis. With the development of bioactive materials and stem cells, more attention has been focused on forming intermediate neural networks to promote neural regeneration and neural circuit reconstruction than on promoting axonal regeneration in the corticospinal tract. Furthermore, technologies to control physical parameters such as electricity, magnetism and ultrasound have been constantly innovated and applied in neural cell fate regulation. Among these advanced novel strategies and technologies, stem cell therapy, biomaterial transplantation, and electromagnetic stimulation have entered into the stage of clinical trials, and some of them have already been applied in clinical treatment. In this review, we outline the overall epidemiology and pathophysiology of SCI, expound on the latest research progress related to neural regeneration and circuit reconstruction in detail, and propose future directions for SCI repair and clinical applications.

show abstract

Section: Intervention and Repair Of Scimentioning

confidence: 99%

Spinal cord injury: molecular mechanisms and therapeutic interventions

Ren

et al. 2023

Sig Transduct Target Ther

View full text Add to dashboard Cite

show abstract

“…For the treatment and rehabilitation of SCI, TCM has been widely used, [ 32 ] including acupuncture, [ 33 ] moxibustion, [ 34 ] and Chinese herbal medicine. [ 35 ] Mechanisms of TCM for SCI involve the inhibition of inflammation, [ 36 ] lipid peroxidation, [ 37 ] neuronal cell death, [ 38 ] improvement of microcirculation, [ 39 ] and promotion of axonal regeneration, [ 40 ] with interactions and interrelations between multiple molecular mechanisms that promote functional recovery after SCI. [ 41 ] This is the advantage of Chinese medicine in treating SCI: multitarget and multi-pathway therapeutic effects.…”

Section: Discussionmentioning

confidence: 99%

Mechanism of Valeriana Jatamansi Jones for the treatment of spinal cord injury based on network pharmacology and molecular docking

Wang,

Lu,

Xiao

et al. 2023

Medicine

View full text Add to dashboard Cite

Spinal cord injury (SCI) is characterized by high rates of disability and death. Valeriana jatamansi Jones (VJJ), a Chinese herbal medicine, has been identified to improve motor function recovery in rats with SCI. The study aimed to analyze the potential molecular mechanisms of action of VJJ in the treatment of SCI. The main ingredients of VJJ were obtained from the literature and the SwissADME platform was used to screen the active ingredients. The Swiss TargetPrediction platform was used to predict the targets of VJJ, and the targets of SCI were obtained from the GeneCards and OMIM databases. The intersecting genes were considered potential targets of VJJ in SCI. The protein–protein interaction network was constructed using the STRING database and the hub genes of VJJ for SCI treatment were screened according to their degree values. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes enrichment analyses were performed using the Metascape database. Cytoscape software was used to construct the “herb-ingredient-target-pathway” network. Preliminary validation was performed using molecular docking via Auto Dock Vina software. A total of 56 active ingredients of VJJ, mainly iridoids, were identified. There were 1493 GO items (P < .01) and 173 signaling pathways (P < .01) obtained from GO and Kyoto Encyclopedia of Genes and Genomes enrichment, including the phosphoinositide-3-kinase (PI3K)–protein kinase B (Akt) signaling pathway, hypoxia-inducible factor 1 signaling pathway, and tumor necrosis factor signaling pathway. Molecular docking revealed that 12 hub genes enriched in the PI3K/Akt signaling pathway had a high binding affinity for the active ingredient of VJJ. VJJ may exert its therapeutic effects on SCI through the iridoid fraction, acting on signal transducer and activator of transcription 3, CASP3, AKT1, tumor necrosis factor, mammalian target of rapamycin, interleukin 6, and other hub genes, which may be related to the PI3K/Akt signaling pathway.

show abstract